Aktis Oncology (NASDAQ:AKTS) Earns Buy Rating from Analysts at HC Wainwright

HC Wainwright started coverage on shares of Aktis Oncology (NASDAQ:AKTS) in a report published on Monday morning, Marketbeat.com reports. The brokerage issued a buy rating and a $30.00 price target on the technology company’s stock. HC Wainwright also issued estimates for Aktis Oncology’s Q4 2025 earnings at ($1.00) EPS, FY2025 earnings at ($2.39) EPS, Q1 2026 earnings at ($0.64) EPS, Q2 2026 earnings at ($0.71) EPS, Q3 2026 earnings at ($0.77) EPS, Q4 2026 earnings at ($0.83) EPS, FY2026 earnings at ($2.95) EPS and FY2027 earnings at ($3.71) EPS.

AKTS has been the subject of several other reports. TD Cowen assumed coverage on Aktis Oncology in a research report on Tuesday, February 3rd. They issued a “buy” rating for the company. Leerink Partners initiated coverage on shares of Aktis Oncology in a research report on Tuesday, February 3rd. They issued an “outperform” rating and a $31.00 price objective on the stock. JPMorgan Chase & Co. began coverage on Aktis Oncology in a research note on Tuesday, February 3rd. They issued an “overweight” rating and a $30.00 price target on the stock. Wall Street Zen raised Aktis Oncology to a “hold” rating in a research report on Saturday, January 17th. Finally, Bank of America assumed coverage on Aktis Oncology in a research note on Tuesday, February 3rd. They issued a “buy” rating and a $34.00 target price on the stock. Five equities research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $31.25.

Aktis Oncology Stock Performance

AKTS stock opened at $19.41 on Monday. Aktis Oncology has a 1-year low of $16.80 and a 1-year high of $29.16. The business’s 50-day simple moving average is $19.76.

Insider Buying and Selling at Aktis Oncology

In related news, Director Helen Susan Kim acquired 835,000 shares of the company’s stock in a transaction dated Monday, January 12th. The shares were bought at an average price of $18.00 per share, for a total transaction of $15,030,000.00. Following the purchase, the director directly owned 5,671,825 shares in the company, valued at approximately $102,092,850. This trade represents a 17.26% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Ansbert Gadicke bought 1,112,777 shares of the firm’s stock in a transaction that occurred on Monday, January 12th. The stock was purchased at an average cost of $18.00 per share, with a total value of $20,029,986.00. Following the completion of the purchase, the insider directly owned 10,260,064 shares of the company’s stock, valued at $184,681,152. This represents a 12.17% increase in their position. The SEC filing for this purchase provides additional information. Insiders have purchased a total of 6,117,776 shares of company stock valued at $110,119,968 in the last ninety days. Insiders own 3.30% of the company’s stock.

Trending Headlines about Aktis Oncology

Here are the key news stories impacting Aktis Oncology this week:

• Positive Sentiment: HC Wainwright reiterated a “Buy” rating and set a $30 price target, which can act as a near-term bullish catalyst by drawing buy-side interest and framing upside vs. the current share price. HC Wainwright Note
• Neutral Sentiment: Recent short-interest reports show “0 shares” and a days-to-cover of 0.0 — this appears to be a reporting anomaly (NaN/inconsistent increases noted) and is not actionable until corrected data is posted. Short Interest Report
• Negative Sentiment: HC Wainwright’s published EPS forecasts project continued and widening losses over the next several years (examples: FY2025 EPS ≈ ($2.39); FY2026 ≈ ($2.95); FY2027 ≈ ($3.71); quarterly FY2026 losses also projected). Those loss projections highlight ongoing cash-burn and execution risk that could pressure valuation absent clear clinical or commercialization progress. EPS Estimates

About Aktis Oncology

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.